ArticleTranslational cancer research2020
Identification of three miRNAs signature as a prognostic biomarker in breast cancer using bioinformatics analysis.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 10 citations in OpenAlex.
- Association of miR-34a with metastatic progression through the FoxO3a-SIRT1 regulatory axis in breast cancer.Turkish journal of medical sciences · 2026Article
- Adaptive multi-omics integration framework for breast cancer survival analysis.Scientific reports · 2025Article
- Article
- Research progress on microRNA-1258 in the development of human cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidences indicated that some miRNAs are dysregulated in breast cancer and involved in cell growth, migration and invasion, differentiation, cell cycle arrest, apoptosis, and autophagy. Our study aims to identify a novel set of biomarkers for predicting the prognosis of breast cancer patients.
methodsWe downloaded clinical information and raw sequencing data from The Cancer Genome Atlas (TCGA) database. We selected samples with miRNA sequencing data and relevant clinical prognostic data for subsequent analysis. The association between miRNA and prognosis function was analyzed by Cox regression analysis. The potential biofunctions of target miRNAs were investigated through bioinformatic analysis.
resultsWe identified 84 differentially expressed miRNAs (DEmiRNAs), among them, 17 were downregulated and 67 were upregulated. We used Kaplan-Meier survival analysis to evaluate the prognostic value of three miRNAs (mir-105-1, mir-301b and mir-1258). We also found that the three-miRNA signature is independent prognostic factors for breast cancer by using Cox regression analysis. It might be participated in different signaling pathways associated with cancer by using functional enrichment analysis, including adherens junction, autophagy, and TGF-beta signaling pathway, ErbB signaling pathway, FoxO signaling pathway.
conclusionsTaken together, three-miRNA signature might be used as a potential predicting prognostic biomarker in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.